Goldman Sachs adjusts positions in Mural Oncology

Published 20/05/2025, 11:24
© Reuters.

NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC reported on Tuesday a series of transactions involving shares of Mural Oncology PLC, reflecting changes in their holdings in the pharmaceutical company. According to a disclosure with the Irish Takeover Panel, the dealings took place on Monday, with Goldman Sachs engaging in both the purchase and sale of Mural Oncology’s USD 0.01 ordinary shares.

The transactions included the purchase of various blocks of shares at prices ranging from $2.7050 to $2.8000, cumulatively adding up to thousands of shares. On the selling side, a smaller quantity of shares was offloaded at $2.5800 and $2.7800. These dealings have resulted in a mixed shift in Goldman Sachs’ long and short positions, with the company now holding 0.86% in long positions and 0.88% in short positions in Mural Oncology.

Additionally, Goldman Sachs reported reducing a long position through CFD transactions, with significant numbers of shares traded at a price of $2.7830. No options transactions were reported in the disclosure.

The trades come amid the context of the Irish Takeover Panel Act of 1997 and Takeover Rules of 2013, which mandate disclosures by persons with interests in relevant securities representing 1% or more. This regulatory framework ensures transparency in the market, particularly during sensitive periods such as takeovers.

Goldman Sachs also confirmed that there are no agreements, arrangements, or understandings relating to the voting rights of any relevant securities under any option or the future acquisition or disposal of any relevant securities.

The disclosure was made public on May 20, 2025, and was accompanied by a supplemental form detailing an open position in a swap transaction, which is set to expire on July 8, 2025.

Investors and market watchers often scrutinize such disclosures for insights into the strategies of major financial institutions like Goldman Sachs and their outlook on companies like Mural Oncology. These transactions are based on a press release statement and provide a glimpse into the trading activities of Goldman Sachs with respect to Mural Oncology shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.